ASH: Eli Lilly pads novel BTK's case amid FDA review. But AbbVie-J&J, BeiGene and AZ need not worry

A new BTK inhibitor could be in town soon. With a different construct compared with the three incumbents, the Eli Lilly candidate is angling for a unique treatment setting. A new BTK inhibitor could be in town soon. With a different construct compared with the three incumbents, the Eli Lilly candidate is angling for a unique treatment setting.